Compare DexCom, Inc. (DXCM) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Las Vegas Sands Corp. — how do they compare? DexCom, Inc. trades at $77.88 (market cap $28.06B), while Las Vegas Sands Corp. trades at $45.27 (market cap $29.68B). The key difference: DexCom, Inc. and Las Vegas Sands Corp. are close in size by market cap, and Las Vegas Sands Corp. pays a 2.46% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | LVS | |
|---|---|---|
Market Cap | $28.06B | $29.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $69.49 |
52-Week Low | $54.84 | $44.78 |
Enterprise Value | $27.03B | $42.07B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
LVS trades at $44.78, down 2.44% with bearish technical signals, though fundamentals show strength with consistent earnings beats and revenue growth from $11.3B in 2024 to $13.0B in 2025. The company maintains solid profitability with 49.59% gross margins and 13.41% net income margin, supported by strong cash flow generation of $3.02B from operations in 2025.
Analyst consensus remains strongly bullish with 61% buy ratings and $65.40 price target, representing 46% upside potential. Key risks include high debt levels with 73.15% debt-to-asset ratio and Macau regulatory exposure, while recent ESG achievements and dividend payments provide stability for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
